DrugEx v2 introduces Pareto-based multi-objective optimization and evolutionary exploration strategies into an RNN reinforcement learning framework for de novo drug design toward multiple protein targets.
Introduces a memory unit that modifies the RL reward function to penalize previously explored chemical scaffolds, substantially increasing the diversity of generated molecules while maintaining relevance to known active ligands.
Proposes MolecularRNN, a graph recurrent model that generates molecular graphs atom-by-atom with 100% validity via valency-based rejection sampling, then shifts property distributions using policy gradient reinforcement learning.
Proposes ORGAN, a framework that extends SeqGAN with domain-specific reward functions via reinforcement learning, enabling tunable generation of molecules optimized for druglikeness, solubility, and synthesizability while maintaining sample diversity.
Introduces a policy-based reinforcement learning method that fine-tunes an RNN pre-trained on ChEMBL SMILES to generate molecules with specified desirable properties, using an augmented episodic likelihood that anchors the agent to its prior while optimizing a user-defined scoring function.
AlphaDrug generates drug candidates for specific protein targets by combining an Lmser Transformer (with hierarchical encoder-decoder skip connections) and Monte Carlo tree search guided by docking scores, achieving higher binding affinities than known ligands on 86% of test proteins.
Proposes Augmented Hill-Climb, a hybrid RL strategy for SMILES-based generative models that improves sample efficiency ~45-fold over REINVENT by filtering low-scoring molecules from the loss computation, with diversity filters to prevent mode collapse.
BindGPT formulates 3D molecular design as autoregressive text generation over combined SMILES and XYZ tokens, using large-scale pre-training and reinforcement learning to achieve competitive pocket-conditioned molecule generation.
Introduces curriculum learning to the REINVENT de novo design platform, decomposing complex drug design objectives into simpler sequential tasks that accelerate agent convergence and improve output quality over standard reinforcement learning.
DrugEx v3 extends scaffold-constrained drug design by introducing a Graph Transformer with adjacency-matrix-based positional encoding, achieving 100% molecular validity and high predicted affinity for adenosine A2A receptor ligands.
A critical reassessment of the PMO benchmark for de novo molecule generation, showing that adding molecular weight, LogP, and diversity filters substantially re-ranks generative models, with Augmented Hill-Climb emerging as the top method.
ChemDFM-R is a 14B-parameter chemical reasoning model that integrates a 101B-token dataset of atomized chemical knowledge. Using a mix-sourced distillation strategy and domain-specific reinforcement learning, it outperforms similarly sized models and DeepSeek-R1 on ChemEval.